Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study
Jorge J. Castillo(Miriam Hospital), Steven P. Treon(Harvard University), Lakshmi Nayak(Dana-Farber Cancer Institute), Christian Buske(Helmholtz Zentrum München), Constantine S. Tam(The Royal Melbourne Hospital), David Simpson(North Shore Hospital), Gilad Itchaki(Rabin Medical Center), Dipti Talaulikar(Australian National University), Samar Issa(Middlemore Hospital), M. Lia Palomba(Memorial Sloan Kettering Cancer Center), Toby A. Eyre(Churchill Hospital), Kenneth H. Shain(Moffitt Cancer Center), Stephen M. Ansell(Mayo Clinic in Arizona), Oren Pasvolsky(Rabin Medical Center), Marzia Varettoni(Policlinico San Matteo Fondazione), Alessandra Tedeschi(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Julio C. Chávez(Moffitt Cancer Center), Jonas Paludo(Rutgers, The State University of New Jersey)
Cited by 100
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k